Open AccessPalbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: a case report
Author(s) -
Fabio Canino,
Luca Moscetti,
Vanni Borghi,
Massimo Dominici,
Federico Piacentini
Publication year - 2021
Publication title -
breast cancer management
Language(s) - English
Resource type - Journals
eISSN - 1758-1931
pISSN - 1758-1923
DOI - 10.2217/bmt-2021-0006
Subject(s) - medicine , palbociclib , breast cancer , cyclin dependent kinase , concomitant , oncology , hormone , human immunodeficiency virus (hiv) , hormone receptor , metastatic breast cancer , cancer , pharmacology , immunology , cell cycle
The use of drugs that affect the cell cycle represents one of the common strategies for the control of some unrelated pathologies, such as chronic viral HIV infections or cancer. The authors report the case of a patient followed for a hormone receptor-positive (HR+)/HER2 negative (HER2-) advanced breast cancer, treated with hormone therapy and CDK 4/6 inhibitors, and a concomitant HIV infection under antiretroviral treatment. The authors consider the function of the sterile alpha motif and HD domain-containing protein-1 (SAMHD1) enzyme, its implications in the control of viral replication and the correlation between its activity and the mechanism of action of the CDK 4/6 inhibitor palbociclib.